The acquisition of a significant stake by an investor like Moshe Arkin often indicates a strong belief in the company's future prospects, which can be a positive signal to the market. His push for the NDA filing of Lonafarnib suggests that he sees potential in this treatment, which could lead to increased investor interest and a potential rise in stock price in the short term. However, the actual impact will depend on market perception and the company's response to the recommendation.